US · BIIB
Biogen Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Cambridge, MA 02142
- Website
- biogen.com
Price · as of 2025-12-31
$187.06
Market cap 28.15B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $217.31 | +16.17% |
| Intrinsic Value(DCF) | $95.22 | -49.1% |
| Graham-Dodd Method(GD) | $124.29 | -33.56% |
| Graham Formula(GF) | $83.49 | -55.37% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $120.61 | $126.01 | $52.33 | $47.25 | $75.50 |
| 2012 | $172.38 | $147.10 | $44.64 | $53.21 | $98.20 |
| 2013 | $328.75 | $244.90 | $99.15 | $70.48 | $257.89 |
| 2014 | $413.35 | $350.74 | $370.28 | $100.39 | $576.03 |
| 2015 | $259.74 | $287.44 | $334.81 | $105.96 | $286.78 |
| 2016 | $292.24 | $301.93 | $308.84 | $123.56 | $241.63 |
| 2017 | $286.10 | $286.36 | $296.90 | $97.25 | $179.35 |
| 2018 | $307.93 | $329.67 | $212.57 | $143.91 | $374.37 |
| 2019 | $317.95 | $374.86 | $264.66 | $197.90 | $460.59 |
| 2020 | $266.13 | $309.57 | $120.84 | $155.01 | $49.94 |
| 2021 | $197.67 | $208.55 | $38.38 | $86.62 | $0.00 |
| 2022 | $256.56 | $258.58 | $51.87 | $157.49 | $22.06 |
| 2023 | $223.24 | $202.54 | $29.28 | $99.42 | $39.14 |
| 2024 | $150.38 | $180.58 | $40.89 | $126.27 | $73.94 |
| 2025 | $188.05 | $217.31 | $31.54 | $124.28 | $83.49 |
AI valuation
Our deep-learning model estimates Biogen Inc.'s (BIIB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $217.31
- Current price
- $187.06
- AI upside
- +16.17%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$95.22
-49.1% upside
Graham-Dodd
$124.29
-33.56% upside
Graham Formula
$83.49
-55.37% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BIIB | Biogen Inc. | $187.06 | 28.15B | +16% | -49% | -34% | -55% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| PODD | Insulet Corporation | $246.61 | 17.36B | -11% | +250% | -84% | -46% | 69.88 | 11.40 | 6.38 | 29.99 | — | 12.82 | 71.63% | 17.50% | 9.12% | 18.12% | 19.54% | 7.87% | 0.69 | 5.94 | 2.78 | 1.81 | 0.57 | -3979.00% | 3073.00% | 2367.00% | 2.19% | 0.84 | 21.40% | 0.00% | 0.00% | 1.12% | 37.15 | 46.60 | 6.50 | 8.10 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| TEVA | Teva Pharmaceutical Indus… | $33.86 | 38.83B | +22% | -53% | — | -55% | 27.36 | 4.91 | 2.25 | 16.76 | — | -3.27 | 51.79% | 12.50% | 8.17% | 21.35% | 10.30% | 3.54% | 2.20 | 2.35 | 1.04 | 0.54 | 4.40 | -18276.00% | 431.00% | 5327.00% | 2.96% | 0.12 | 5.48% | 0.00% | 0.00% | 2.46% | 24.40 | 45.84 | 3.05 | 0.85 |
| UTHR | United Therapeutics Corpo… | $503.90 | 22.79B | -28% | -44% | -38% | +9% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- CEO
- Christopher A. Viehbacher
- Employees
- 7.61K
- Beta
- 0.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($95.22 ÷ $187.06) − 1 = -49.1% (DCF, example).